Biocartis, Exploit Technologies Ink MDx Assay Development Deal

Jul 10, 2017

|

NEW YORK (GenomeWeb) – Biocartis announced today that it has extended its partnership with Exploit Technologies (ETPL) — the commercialization arm of Singapore's Agency for Science, Technology, and Research — to develop molecular diagnostic assays, including one for breast cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

For In Vitro Diagnostic Materials: Efficacy vs. Thimerosal and Sodium Azide

Development of a Quantitative Lateral Flow Test Using Estapor Europium Microspheres

Performance of Estapor Microspheres and Hi-Flow Plus Membranes in a Lateral Flow Assay for Human Chorionic Gonadotropin (hCG)

ProClin 300 Preservative: An In-Depth Technical Analysis

Apr

16

Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Apr

29

Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May

13

Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May

18

Featured Webinar

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.

Menu

Biocartis, Exploit Technologies Ink MDx Assay Development Deal

To read the full story....

Breaking News

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

NIH Funds $33M in COVID-19 Testing Projects for Safe Return of Students, Staff to School

Cancer Dx Firm C2i Genomics Raises $100M in Financing

Centogene Q4 Revenues Grow Almost Fivefold, Driven by COVID-19 Testing

Thermo Fisher Scientific to Acquire Contract Research Organization PPD for $17.4B

Snibe Diagnostic Obtains CE Mark for HIV Chemiluminescence Immunoassay

Featured White Papers

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

What's Popular?

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

FDA Grants EUAs for SARS-CoV-2 Tests From Clinical Enterprise, Qorvo Biotechnologies

FDA-Led Group Evaluates Performance of RUO Liquid Biopsy Assays to Inform Practice Guidelines

Labs Craft SARS-CoV-2 Variant Genotyping Assays for Screening, Surveillance

Sponsorships